Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine

Author:

Goyal ParagORCID,Pai Harish Venkatraman,Kodali Phanichand,Vats Bhavesh,Vajpai Navratna,Annegowda Shankara,Mane Krishnappa,Mohan Shamini,Saxena Shruti,Veerabhadraia Anil Bangalore,Palande Milee,Nair Preethy Sasankan,More Digvijay Chandrashekar,Karudumpa Umamaheshwara Rao,Jyothirmai Kunala,Bhattacharya Adroha,Almeida Frida,Khyade Santosh Gulab,Gouda Shankara,Ranayhossaini Daniel J.,Moole Praveen Reddy,Smith Jeffrey P.,Barve Abhijit,Melarkode Ramakrishnan,Ullanat Rajesh

Abstract

Insulin glargine is a long-acting analogue of human insulin that has been used to manage hyperglycemia in patients with diabetes mellitus (DM) for nearly 20 years. Insulin glargine has a relatively constant concentration-time profile that mimics basal levels of insulin and allows for once-daily administration. MYL-1501D is a biosimilar insulin glargine designed to offer greater access of insulin glargine to patients, with comparable efficacy and safety to the marketed reference product. We conducted a comprehensive panel of studies based on a formal analysis of critical quality attributes to characterize the structural and functional properties of MYL-1501D and reference insulin glargine products available in the United States and European Union. MYL-1501D was comprehensively shown to have high similarity to the reference products in terms of protein structure, metabolic activity (both in vitro cell-based assays and in vivo rabbit bioassays), and in vitro cell-based assays for mitogenic activity. The structural analyses demonstrated that the primary protein sequence was identical, and secondary and tertiary structures are similar between the proposed biosimilar and the reference products. Insulin receptor binding affinity and phosphorylation studies also established analytical similarity. MYL-1501D demonstrated high similarity in different metabolic assays of glucose uptake, adipogenesis activity, and inhibition of stimulated lipolysis. Rabbit bioassay studies showed MYL-1501D and EU-approved insulin glargine are highly similar to US-licensed insulin glargine. These product quality studies show high similarity between MYL-1501D and licensed or approved insulin glargine products and suggest the potential of MYL-1501D as an alternative cost-effective treatment option for patients and clinicians.

Funder

Viatris Inc.

Biocon Limited

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference32 articles.

1. European Medicines Agency. Lantus Authorisation Details. 2000 Sep 6 [cited 30 Oct 2020]. In: European Medicines Agency [Internet]. Amsterdam, The Netherlands: European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lantus#authorisation-details-section.

2. Lantus [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2019.

3. Figueiredo ACMG, Silva EN, Pereira MG. Long-acting insulin analogues for type 1 diabetes: an overview of systematic reviews and meta-analysis of randomized controlled trials;FO Laranjeira;PLoS One,2018

4. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: a post hoc, pooled, patient-level analysis of 6 randomized controlled trials.;F Porcellati;Medicine (Baltimore),2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3